ReviewBritish journal of cancer2020
Effective delivery of Complex Innovative Design (CID) cancer trials-A consensus statement.
Review in British journal of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Trial
- Clinical Trials of Liposomes in Children's Anticancer Therapy: A Comprehensive Analysis of Trials Registered on ClinicalTrials.gov.International journal of nanomedicine · 2022Trial
- Oncology drug development in the UK: analysis of the past 25 years and focus on the 2026 reboot of the clinical trial regulatory framework.British journal of cancer · 2026Article
- Value-adaptive clinical trial designs for efficient delivery of publicly funded trials - a discussion of methods, case studies, opportunities and challenges.BMC medical research methodology · 2025Article
- Use of Bayesian approaches in oncology clinical trials: A cross-sectional analysis.Frontiers in pharmacology · 2025Article
- A maturity model for the scientific review of clinical trial designs and their informativeness.Trials · 2024Article
- Optimizing the FDA's Project Optimus: opportunities and challenges.Nature reviews. Clinical oncology · 2024Article
- Article
- Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective.British journal of cancer · 2023Article
- Duplicated network meta-analysis in advanced prostate cancer: a case study and recommendations for change.Systematic reviews · 2022Article
- Article
- Practical guidance for planning resources required to support publicly-funded adaptive clinical trials.BMC medicine · 2022Article
- Understanding the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials.Breast (Edinburgh, Scotland) · 2022Article
- Study designs for clinical trials applied to personalised medicine: a scoping review.BMJ open · 2022Article
- Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer.Clinical trials (London, England) · 2022Article
- Real World Data in Health Technology Assessment of Complex Health Technologies.Frontiers in pharmacology · 2022Article
- Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy.Journal of Crohn's & colitis · 2021Review
- Review
- Statistical consideration when adding new arms to ongoing clinical trials: the potentials and the caveats.Trials · 2021Article
- Exploring Heterogeneity in Histology-Independent Technologies and the Implications for Cost-Effectiveness.Medical decision making : an international journal of the Society for Medical Decision Making · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
The traditional cancer drug development pathway is increasingly being superseded by trials that address multiple clinical questions. These are collectively termed Complex Innovative Design (CID) trials. CID trials not only assess the safety and toxicity of novel anticancer medicines but also their efficacy in biomarker-selected patients, specific cancer cohorts or in combination with other agents. They can be adapted to include new cohorts and test additional agents within a single protocol. Whilst CID trials can speed up the traditional route to drug licencing, they can be challenging to design, conduct and interpret. The Experimental Cancer Medicine Centres (ECMC) network, funded by the National Institute for Health Research (NIHR), Cancer Research UK (CRUK) and the Health Boards of Wales, Northern Ireland and Scotland, formed a working group with relevant stakeholders from clinical trials units, the pharmaceutical industry, funding bodies, regulators and patients to identify the main challenges of CID trials. The working group generated ten consensus recommendations. These aim to improve the conduct, quality and acceptability of oncology CID trials in clinical research and, importantly, to expedite the process by which effective treatments can reach cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.